Tarsier Receives FDA Agreement Under SPA for Tarsier-04 Phase 3 Trial of TRS01
Tarsier Pharma Announces Successful Type C Meeting with FDA for TRS01
TEL-AVIV, Israel, Aug. 23, 2023 /PRNewswire/ -- Tarsier Pharma, an advanced clinical stage biotechnology company developing dazdotuftide (formerly known as TRS), a first-in-class New Chemical Entity for patients with immune-mediated diseases, today announced results from the noninfectious anterior uveitis TRS4VISION Trial. While the primary endpoint was not met, a post hoc analysis of the data demonstrates the much-anticipated clinical profile of a blend of safety and actively resolving inflammation that is promising in the treatment of noninfectious uveitis and specifically in uveitic glaucoma.
Tarsier Pharma, an advanced clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for blinding ...
TEL AVIV, Israel, Sept. 22, 2021 /PRNewswire/ -- Tarsier Pharma, an advanced clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced the initiation of its Phase 3 trial TRS4VISION by randomizing the first patient for treatment.
TEL-AVIV, Israel, Aug. 24, 2021 /PRNewswire/ -- Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. Strategic and new investors alongside existing investors participated in this transaction.
TEL-AVIV, Israel, April 26, 2021 /PRNewswire/ -- Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S Food and Drug Administration (FDA), and has received positive feedback on the clinical development plan for TRS02.
TEL-AVIV, Israel, April 26, 2021 /PRNewswire/ -- Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S Food and Drug Administration (FDA), and has received positive feedback on the clinical development plan for TRS02.